Study on Using TROP2-PET and 18F-FDG PET to Predict the Efficacy of Anti TROP2 ADC Treatment in Advanced Breast Cancer

NCT07471776 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

45

Enrollment

OTHER

Sponsor class

Conditions

Metastatic Breast Cancer ( HER2 Negative)

Interventions

DRUG: Sacituzumab Govitecan、Datopotamab deruxtecan、Sacituzumab tirumotecan
DIAGNOSTIC_TEST: 68Ga-TROP2 PET/CT Imaging
DIAGNOSTIC_TEST: 18F-FDG PET Imaging

Sponsor

Fudan University